Trial Profile

An Open-label, Uncontrolled Study of ONO-7913, ONO-4538 and the Standard of Care FOLFOX in Combination With Bevacizumab or Cetuximab as First-line Treatment in Patients With Unresectable Advanced or Recurrent Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil (Primary) ; Levofolinic acid (Primary) ; Magrolimab (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary)
Indications Colorectal cancer
Focus Adverse reactions
Sponsors Ono Pharmaceutical

13 Sep 2024 Planned End Date changed from 31 Jan 2025 to 31 Dec 2027.
13 Sep 2024 Planned primary completion date changed from 31 Jan 2025 to 31 Dec 2027.
09 Aug 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com